Takeda Pharma (TKPYY) 21.4850 $TKPYY
Seattle Genetics/Takeda Adectris' Label Expanded in the EU
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:21PM CDT
Seattle Genetics, Inc. (SGEN) announced that its partner Takeda Pharmaceutical Company Limited (TKPYY) has received marketing authorization for the label expansion of its lymphoma drug, Adcetris.
JNJ: 122.85 (+0.34), SGEN: 41.45 (+0.51), PFE: 36.12 (+0.35)
Takeda Receives European Commission Approval of ADCETRIS(R) (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
BusinessWire - Wed Jul 06, 7:00AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) has extended the current conditional marketing authorization of ADCETRIS(R) (brentuximab vedotin) and approved ADCETRIS for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT). The decision follows a positive opinion from the Committee for Medicinal Products for Human Use on May 26, 2016.
Takeda Submits a New Drug Application for Novel, Oral Proteasome Inhibitor Ixazomib in Japan
BusinessWire - Tue Jul 05, 7:00AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it has submitted a New Drug Application ("NDA"
to the Ministry of Health, Labour and Welfare in Japan for ixazomib, the first oral proteasome inhibitor for the treatment of relapsed or refractory multiple myeloma.
Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. Rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease
PR Newswire Europe - Tue Jul 05, 1:01AM CDT
Takeda Pharmaceutical Company Limited ("Takeda" and TiGenix NV ("TiGenix" today announced that the companies have entered into an exclusive ex-U.S. license, development and commercialization agreement for Cx601, a suspension of allogeneic adipose-derived stem cells (eASC) injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn's disease. TiGenix will receive an upfront cash payment of EUR25 million. TiGenix will be eligible to receive additional regulatory and sales milestone payments for up to a potential total of EUR355 million and double digit royalties on net sales by Takeda. The first anticipated milestone payment is EUR15 million upon obtaining the Marketing Authorization of Cx601 in the European Economic Area (EEA). In addition, Takeda will make an equity investment of EUR10 million in the share capital of TiGenix within the next 12 months.
Takeda to Partner with Altos Therapeutics to Develop Promising Compound for the Treatment of Gastroparesis
BusinessWire - Sun Jul 03, 6:00PM CDT
Takeda Pharmaceutical Company Limited (TOKYO:4502) and Altos Therapeutics LLC today jointly announced the companies have entered into a definitive agreement to further the development of Altos's proprietary compound ATC-1906. Additionally, the agreement includes an exclusive option for Takeda to acquire Altos beginning on the date of the agreement and continuing for a period of time following the completion of ongoing Phase 1 studies of ATC-1906. The parties envision future development of ATC-1906 for the treatment of gastroparesis (GP) and its symptoms.
7 Ultra Safe Stocks to Wait Out Brexit Results
Swarup Gupta - Zacks Investment Research - Thu Jun 23, 9:28AM CDT
Opinion polls suggest that it is difficult to determine which way the referendum over Brexit will go.
NTT: 48.54 (-0.20), WMT: 73.84 (+0.31), TSN: 68.92 (+1.26), NGG: 73.05 (+0.87), DTE: 99.14 (+0.95)
Takeda and M2Gen Collaborate with ORIEN to Speed Clinical Development and Discovery of Cancer Treatments Through Health Informatics
PR Newswire - Thu Jun 16, 6:30AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) and M2Gen®, a healthcare informatics solutions company, have established a new collaboration to generate broad genomic data from consenting cancer patients. Under the agreement, Takeda will help build the Oncology Research Information Exchange Network (ORIEN) AvatarTM Research Program based on the Total Cancer Care® Protocol, a prospective observational study enrolling patients with various cancers, and access information generated under this program.
EXAMINE Trial Post-Hoc Analyses of Mortality Data Regarding Cardiovascular Safety of Alogliptin Presented at American Diabetes Association's 76th Scientific Sessions and Published in Diabetes Care
PR Newswire Europe - Sat Jun 11, 12:39PM CDT
Takeda Pharmaceutical Company Limited [TSE: 4502 [http://www.takeda.com/investor-information/]], ("Takeda" announced the publication of a post-hoc analysis from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial (CVOT), which suggested that in patients with Type 2 diabetes and recent acute coronary syndrome (ACS), the risk of death, including CV death, was not higher with the dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin compared to placebo during a median follow-up period of 18 months.(1) Trial results reported that in both groups of patients the occurrence of an additional non-fatal CV event, including myocardial infarction (MI), stroke, and unstable angina, was common and increased the risk of death, particularly after hospitalization for heart failure (HHF). This data was presented at the American Diabetes Association's 76(th) Scientific Sessions, and also published in Diabetes Care.
Theravance Biopharma Signs Licensing Deal with Takeda
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:23AM CDT
Theravance Biopharma (TBPH) has entered into a global license, development and commercialization agreement with Takeda (TKPYY) for TD-8954.
PFE: 36.12 (+0.35), TBPH: 23.46 (+0.46), BMY: 75.28 (+1.20)
Takeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders
PR Newswire Europe - Wed Jun 08, 7:52AM CDT
Deal Provides Takeda Global Rights to Selective 5-HT4 Agonist; Highlights Takeda's Commitment to Gastroenterology as a Core Therapeutic Area
TBPH: 23.46 (+0.46)
Roivant Sciences and Takeda Launch Myovant Sciences to Develop Innovative Therapeutics for Women's Health and Prostate Cancer
PR Newswire - Mon Jun 06, 6:00AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) and Roivant Sciences Ltd. today announced the formation of Myovant Sciences Ltd. ("Myovant" , a biopharmaceutical company focused on delivering innovative women's health and prostate cancer solutions by efficiently advancing new medicines to market that have the potential to improve the lives of millions of patients. In addition, Lynn Seely, MD, an endocrinologist who led the development of XTANDI® (enzalutamide) for the treatment of prostate cancer as the Chief Medical Officer of Medivation from 2005 to 2015, was named the President & Chief Executive Officer of Myovant Sciences, Inc.
Trintellix (vortioxetine) Now Available in U.S. Pharmacies
PR Newswire - Wed Jun 01, 9:00AM CDT
Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4502), and Lundbeck announced today that Trintellix (vortioxetine), a once-daily oral antidepressant indicated for the treatment of major depressive disorder (MDD) in adults, is now available in United States pharmacies.
Takeda Receives Positive CHMP Opinion for ADCETRIS(R) (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
BusinessWire - Fri May 27, 7:30AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the current conditional approval of ADCETRIS(R) (brentuximab vedotin) and recommended its approval for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplantation (ASCT). On average 50 percent of Hodgkin lymphoma patients relapse after ASCT and those patients with additional risk factors can be at even higher risk of relapse. ADCETRIS after ASCT is a new treatment paradigm based on the largest randomized study ever conducted in relapsed or refractory Hodgkin lymphoma. The AETHERA Phase 3 trial is the first completed study that has explored consolidation treatment immediately following ASCT as a way of extending the effect of transplant for prevention of relapse among people with Hodgkin lymphoma. The use of ADCETRIS in this setting may provide a meaningful treatment option where none currently exist for patients.
Takeda Provides Update on EU Marketing Authorization Application for NINLARO(R) (ixazomib) in Relapsed/Refractory Multiple Myeloma
BusinessWire - Fri May 27, 7:00AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion, recommending against the authorization of NINLARO(R) (ixazomib) capsules, an oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma. Takeda intends to appeal this opinion and request a re-examination by the CHMP.
Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week (DDW) Annual Meeting
PR Newswire Europe - Mon May 23, 11:49AM CDT
Takeda Pharmaceutical Company Limited [TSE: 4502 [http://www.takeda.com/investor-information/]], ("Takeda" today announced the oral presentations of two data analyses: one evaluating the optimal position of vedolizumab in the ulcerative colitis (UC) treatment paradigm, and a second separate analysis assessing whether early vedolizumab trough levels were associated with subsequent drug efficacy. Findings were presented during the 2016 Digestive Disease Week (DDW) Annual Meeting in San Diego, California, and were included in a total of 13 Takeda-sponsored vedolizumab or inflammatory bowel disease (IBD)-focused abstracts, including four oral presentations and nine posters.
Long-Term Integrated Safety Analysis Published in Gut Reports a Favorable Benefit-Risk Profile for Vedolizumab in an Extended Treatment Period
PR Newswire Europe - Thu May 12, 8:02AM CDT
This analysis examining treatment with vedolizumab in patients with moderately to severely active ulcerative colitis or Crohn's disease observed no significant safety concerns
Seattle Genetics/Takeda Adectris' Label Expanded in the EU
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:21PM CDT
Seattle Genetics, Inc. (SGEN) announced that its partner Takeda Pharmaceutical Company Limited (TKPYY) has received marketing authorization for the label expansion of its lymphoma drug, Adcetris.
JNJ: 122.85 (+0.34), SGEN: 41.45 (+0.51), PFE: 36.12 (+0.35)
Takeda Receives European Commission Approval of ADCETRIS(R) (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
BusinessWire - Wed Jul 06, 7:00AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) has extended the current conditional marketing authorization of ADCETRIS(R) (brentuximab vedotin) and approved ADCETRIS for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT). The decision follows a positive opinion from the Committee for Medicinal Products for Human Use on May 26, 2016.
Takeda Submits a New Drug Application for Novel, Oral Proteasome Inhibitor Ixazomib in Japan
BusinessWire - Tue Jul 05, 7:00AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it has submitted a New Drug Application ("NDA"
to the Ministry of Health, Labour and Welfare in Japan for ixazomib, the first oral proteasome inhibitor for the treatment of relapsed or refractory multiple myeloma. Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. Rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease
PR Newswire Europe - Tue Jul 05, 1:01AM CDT
Takeda Pharmaceutical Company Limited ("Takeda"
and TiGenix NV ("TiGenix" today announced that the companies have entered into an exclusive ex-U.S. license, development and commercialization agreement for Cx601, a suspension of allogeneic adipose-derived stem cells (eASC) injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn's disease. TiGenix will receive an upfront cash payment of EUR25 million. TiGenix will be eligible to receive additional regulatory and sales milestone payments for up to a potential total of EUR355 million and double digit royalties on net sales by Takeda. The first anticipated milestone payment is EUR15 million upon obtaining the Marketing Authorization of Cx601 in the European Economic Area (EEA). In addition, Takeda will make an equity investment of EUR10 million in the share capital of TiGenix within the next 12 months. Takeda to Partner with Altos Therapeutics to Develop Promising Compound for the Treatment of Gastroparesis
BusinessWire - Sun Jul 03, 6:00PM CDT
Takeda Pharmaceutical Company Limited (TOKYO:4502) and Altos Therapeutics LLC today jointly announced the companies have entered into a definitive agreement to further the development of Altos's proprietary compound ATC-1906. Additionally, the agreement includes an exclusive option for Takeda to acquire Altos beginning on the date of the agreement and continuing for a period of time following the completion of ongoing Phase 1 studies of ATC-1906. The parties envision future development of ATC-1906 for the treatment of gastroparesis (GP) and its symptoms.
7 Ultra Safe Stocks to Wait Out Brexit Results
Swarup Gupta - Zacks Investment Research - Thu Jun 23, 9:28AM CDT
Opinion polls suggest that it is difficult to determine which way the referendum over Brexit will go.
NTT: 48.54 (-0.20), WMT: 73.84 (+0.31), TSN: 68.92 (+1.26), NGG: 73.05 (+0.87), DTE: 99.14 (+0.95)
Takeda and M2Gen Collaborate with ORIEN to Speed Clinical Development and Discovery of Cancer Treatments Through Health Informatics
PR Newswire - Thu Jun 16, 6:30AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) and M2Gen®, a healthcare informatics solutions company, have established a new collaboration to generate broad genomic data from consenting cancer patients. Under the agreement, Takeda will help build the Oncology Research Information Exchange Network (ORIEN) AvatarTM Research Program based on the Total Cancer Care® Protocol, a prospective observational study enrolling patients with various cancers, and access information generated under this program.
EXAMINE Trial Post-Hoc Analyses of Mortality Data Regarding Cardiovascular Safety of Alogliptin Presented at American Diabetes Association's 76th Scientific Sessions and Published in Diabetes Care
PR Newswire Europe - Sat Jun 11, 12:39PM CDT
Takeda Pharmaceutical Company Limited [TSE: 4502 [http://www.takeda.com/investor-information/]], ("Takeda"
announced the publication of a post-hoc analysis from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial (CVOT), which suggested that in patients with Type 2 diabetes and recent acute coronary syndrome (ACS), the risk of death, including CV death, was not higher with the dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin compared to placebo during a median follow-up period of 18 months.(1) Trial results reported that in both groups of patients the occurrence of an additional non-fatal CV event, including myocardial infarction (MI), stroke, and unstable angina, was common and increased the risk of death, particularly after hospitalization for heart failure (HHF). This data was presented at the American Diabetes Association's 76(th) Scientific Sessions, and also published in Diabetes Care. Theravance Biopharma Signs Licensing Deal with Takeda
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:23AM CDT
Theravance Biopharma (TBPH) has entered into a global license, development and commercialization agreement with Takeda (TKPYY) for TD-8954.
PFE: 36.12 (+0.35), TBPH: 23.46 (+0.46), BMY: 75.28 (+1.20)
Takeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders
PR Newswire Europe - Wed Jun 08, 7:52AM CDT
Deal Provides Takeda Global Rights to Selective 5-HT4 Agonist; Highlights Takeda's Commitment to Gastroenterology as a Core Therapeutic Area
TBPH: 23.46 (+0.46)
Roivant Sciences and Takeda Launch Myovant Sciences to Develop Innovative Therapeutics for Women's Health and Prostate Cancer
PR Newswire - Mon Jun 06, 6:00AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) and Roivant Sciences Ltd. today announced the formation of Myovant Sciences Ltd. ("Myovant"
, a biopharmaceutical company focused on delivering innovative women's health and prostate cancer solutions by efficiently advancing new medicines to market that have the potential to improve the lives of millions of patients. In addition, Lynn Seely, MD, an endocrinologist who led the development of XTANDI® (enzalutamide) for the treatment of prostate cancer as the Chief Medical Officer of Medivation from 2005 to 2015, was named the President & Chief Executive Officer of Myovant Sciences, Inc. Trintellix (vortioxetine) Now Available in U.S. Pharmacies
PR Newswire - Wed Jun 01, 9:00AM CDT
Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4502), and Lundbeck announced today that Trintellix (vortioxetine), a once-daily oral antidepressant indicated for the treatment of major depressive disorder (MDD) in adults, is now available in United States pharmacies.
Takeda Receives Positive CHMP Opinion for ADCETRIS(R) (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
BusinessWire - Fri May 27, 7:30AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the current conditional approval of ADCETRIS(R) (brentuximab vedotin) and recommended its approval for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplantation (ASCT). On average 50 percent of Hodgkin lymphoma patients relapse after ASCT and those patients with additional risk factors can be at even higher risk of relapse. ADCETRIS after ASCT is a new treatment paradigm based on the largest randomized study ever conducted in relapsed or refractory Hodgkin lymphoma. The AETHERA Phase 3 trial is the first completed study that has explored consolidation treatment immediately following ASCT as a way of extending the effect of transplant for prevention of relapse among people with Hodgkin lymphoma. The use of ADCETRIS in this setting may provide a meaningful treatment option where none currently exist for patients.
Takeda Provides Update on EU Marketing Authorization Application for NINLARO(R) (ixazomib) in Relapsed/Refractory Multiple Myeloma
BusinessWire - Fri May 27, 7:00AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion, recommending against the authorization of NINLARO(R) (ixazomib) capsules, an oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma. Takeda intends to appeal this opinion and request a re-examination by the CHMP.
Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week (DDW) Annual Meeting
PR Newswire Europe - Mon May 23, 11:49AM CDT
Takeda Pharmaceutical Company Limited [TSE: 4502 [http://www.takeda.com/investor-information/]], ("Takeda"
today announced the oral presentations of two data analyses: one evaluating the optimal position of vedolizumab in the ulcerative colitis (UC) treatment paradigm, and a second separate analysis assessing whether early vedolizumab trough levels were associated with subsequent drug efficacy. Findings were presented during the 2016 Digestive Disease Week (DDW) Annual Meeting in San Diego, California, and were included in a total of 13 Takeda-sponsored vedolizumab or inflammatory bowel disease (IBD)-focused abstracts, including four oral presentations and nine posters. Long-Term Integrated Safety Analysis Published in Gut Reports a Favorable Benefit-Risk Profile for Vedolizumab in an Extended Treatment Period
PR Newswire Europe - Thu May 12, 8:02AM CDT
This analysis examining treatment with vedolizumab in patients with moderately to severely active ulcerative colitis or Crohn's disease observed no significant safety concerns
